NeuroKaire On-Page SEO Recommendations — Meta Titles, Descriptions & Heading Structure

Pages Covered (per Website Update Plan Navigation)

Homepage /
How It Works /technology
For Individuals /patients
For Clinicians /brightkaire-clinicians
Evidence / Resources /resources
About /about-us

Navigation labels above reflect the planned Phase 1 header structure. "Evidence" and "Resources" share /resources for now; the plan contemplates a dedicated /evidence page later.

Executive Summary

Pages Optimized

Titles to Fix

Meta Descriptions to Fix

H1s to Improve

H2s Recommended

Systemic Issues Resolved

"(formerly GenetikaPlus)" removed from all titles — saves 23–25 characters per title, eliminates outdated branding baggage
All titles brought to ≤60 characters — prevents SERP truncation (all 7 were over or under threshold)
All meta descriptions set to 120–155 characters — 1 was missing entirely, 2 exceeded 200 characters
Primary keywords backed by actual search volume data — every recommended title uses keywords with documented monthly search volume from Content Gap and Keyword List analysis, replacing zero-volume terms like "precision psychiatry" (30/mo) and "antidepressant selection" (10/mo)
All H1s unique, ≤70 characters, keyword-aligned — 1 was 89 chars, 2 were generic ("About Us", "Resources"), 1 was 72 chars with trailing period
H2 structures sourced directly from Website Update Plan section headings — ensures content/SEO alignment from Phase 1 through Phase 5

Keyword Volume Backing

Every title and meta description recommendation is backed by keyword volume and difficulty data from three sources:

Content Gap Analysis — keywords competitors (Genomind, GeneSight, GeneDx, Tempus) rank for but NeuroKaire does not
Keyword List — terms NeuroKaire already ranks for (position 1) with high search volume
Expanded Keyword Research — thematic keyword clusters with volume, difficulty, and relevance scoring

Methodology & Criteria

Title Tags: ≤60 characters (ideal 50–60). Primary keyword front-loaded with documented search volume. Brand name ("NeuroKaire") at end via pipe separator. Unique per page.
Meta Descriptions: 120–155 characters. Multiple high-volume keywords included naturally. Compelling value proposition or CTA. Unique per page.
H1 Tags: Exactly one per page. ≤70 characters. Contains primary keyword. Different from (but complementary to) title tag.
H2 Tags: Define page content hierarchy. Sourced from the exact section headings in the Website Update Plan to ensure alignment between SEO structure and content strategy.
Keyword Strategy: Based on 2026 Keyword Analysis. Title keywords selected for: (1) search volume ≥500/mo, (2) keyword difficulty ≤30, (3) direct relevance to page content, (4) no cannibalization across pages.
Tone Alignment: Per Update Plan guiding principles — clarity over warmth, confidence over enthusiasm, reduce uncertainty rather than fear.

1. Homepage / Phase 2

genetic testing for medication 1,500/mo · KD 24 depression medication 49,500/mo antidepressant medication 40,500/mo · Rank #1 antidepressant trial-and-error

Meta Title (Target: 50–60 chars)

80 chars — too long 746px — will truncate "(formerly GenetikaPlus)"

Current Transforming Psychiatry and Neurology Care | NeuroKaire (formerly GenetikaPlus)

↓

Recommended Genetic Testing for Depression Medication | NeuroKaire (54 characters) • "genetic testing for medication" = 1,500/mo, KD 24 • "depression medication" = 49,500/mo parent topic

Meta Description (Target: 120–155 chars)

205 chars — too long "(formerly GenetikaPlus)" No CTA

Current NeuroKaire (formerly GenetikaPlus) is pioneering a personalized treatment approach for psychiatric and neurological conditions, transforming the way these diseases are treated and new drugs are discovered.

↓

Recommended Move beyond antidepressant trial-and-error. NeuroKaire genetic testing reveals how your neurons respond to depression medication before treatment. (146 characters) • "antidepressant" = 40,500/mo parent • "depression medication" = 49,500/mo • "genetic testing" = cluster head • Echoes Update Plan hero headline

H1 Heading (Target: ≤70 chars)

Generic — no product or keyword

Current Transforming brain health (25 characters)

↓

Recommended Move beyond antidepressant trial-and-error (42 characters — exact Phase 2, Section 1 hero headline from Update Plan)

Recommended H2 Structure (sourced from Update Plan Section 2.2)

Why choosing the right antidepressant is so difficult Update Plan §2.2, Section 3
Measuring response before treatment begins Update Plan §2.2, Section 4
How it works Update Plan §2.2, Section 5
What patients and clinicians are saying — Testimonials (Section 6)
Find your path — Audience routing: For Individuals | For Clinicians (Section 7)

2. How It Works /technology Phase 1

Nav label changes from "Technology" → "How It Works" per Update Plan §1.1. Title and H1 should reflect this new intent-first label.

antidepressant medication 40,500/mo · Rank #1 depression medication 49,500/mo parent topic pharmacogenomics testing 590/mo · Rank #1 (differentiate from) antidepressant response testing

Meta Title (Target: 50–60 chars)

Generic "Technology" — misaligned with new nav label "(Formerly GenetikaPlus)"

Current Technology | NeuroKaire (Formerly GenetikaPlus)

↓

Recommended How Antidepressant Response Testing Works | NeuroKaire (54 characters) • "antidepressant" = 40,500/mo parent, Rank #1 • Matches "How It Works" nav label • Describes neuronal response testing without conflating with pharmacogenomics

Meta Description (Target: 120–155 chars)

130 chars — in range but vague No mention of neurons, AI, or CLIA

Current Explore the innovative technology at NeuroKaire: advancing psychiatry and neurology through cutting-edge research and development.

↓

Recommended See how NeuroKaire measures antidepressant response at the neuronal level using patient-derived neurons, genomics, and AI. CLIA-certified testing. (146 characters) • "antidepressant" = 40,500/mo parent, Rank #1 • "neuronal level" differentiates from pharmacogenomic competitors • CLIA credibility signal

H1 Heading (Target: ≤70 chars)

89 chars — severely over limit

Current Leveraging stem cell technology, genomics and AI to transform mental health and neurology (89 characters)

↓

Recommended How BrightKaire antidepressant testing works (44 characters)

Recommended H2 Structure (sourced from current page + Update Plan)

Multi-modal insights drive evidence-based care — Existing section (retain)
From blood sample to treatment insight — Step-by-step process: iPSC → neuronal plasticity → AI → brain signature
CNS disorders we work on — Existing section (retain)
Technology in action — Data proof points: 1.5M+ data points, 2,500+ features, 120K+ patients

3. For Individuals /patients Phase 3

Nav label is "For Individuals" per Update Plan §1.1 (audience-correct). Title and H1 should reflect patient-first, relief-focused language.

genetic testing for antidepressants 1,200/mo · KD 6 antidepressant medication 40,500/mo · Rank #1 genetic test for depression medication 210/mo · Rank #1 which antidepressant is right for me

Meta Title (Target: 50–60 chars)

81 chars — too long "(formerly GenetikaPlus)"

Current Personalized Mental Health Treatment Options | NeuroKaire (formerly GenetikaPlus)

↓

Recommended Genetic Testing for Antidepressants | NeuroKaire (48 characters) • "genetic testing for antidepressants" = 1,200/mo, KD 6 • Content Gap: Genomind ranks #10, GeneSight #1 — very low difficulty win

Meta Description (Target: 120–155 chars)

308 chars — severely too long "brain-in-a-dish therapy" — confusing for patients

Current Learn how personalized mental health treatments, brain-in-a-dish therapy, and precision psychiatry testing provide clarity for patients exploring better depression and anxiety care. NeuroKaire reports provide actionable insights to guide treatment decisions, potentially leading to improved patient outcomes.

↓

Recommended Which antidepressant medication is right for you? BrightKaire genetic testing for antidepressants guides depression treatment before trial-and-error. (149 characters) • "antidepressant medication" = 40,500/mo, Rank #1 • "genetic testing for antidepressants" = 1,200/mo, KD 6 • "depression treatment" = parent topic

H1 Heading (Target: ≤70 chars)

Trailing period in H1 Generic "personalized" framing

Current Personalized Mental Health Treatments with BrightKaire. (55 characters)

↓

Recommended Understand which antidepressants may work for you (49 characters — exact language from Update Plan §2.2, Section 7 audience pathway)

Recommended H2 Structure (sourced from Update Plan §3.1 & §3.2)

Your brain, your blueprint — Why BrightKaire is different (existing section, retained)
What happens next Update Plan §3.1 — 4-step process block
Order & intake → Blood sample collection → Laboratory analysis → Review with your clinician
Who can benefit from BrightKaire — Existing section (retain)
What patients are saying — Testimonials (existing, retain)
Frequently asked questions Update Plan §3.2
Top 5 patient FAQs in accordion + FAQ schema markup for AEO

4. For Clinicians /brightkaire-clinicians Phase 3

Nav label is "For Clinicians" per Update Plan §1.1. Messaging should center on clinical confidence and biological insight supporting judgment.

genetic testing for psychiatric medications 500/mo · KD 9 treatment resistant depression 18,100/mo · Rank #1 antidepressant side effects 14,800/mo · Rank #1 pharmacogenomic testing for antidepressants 100/mo · KD 6

Meta Title (Target: 50–60 chars)

70 chars — over limit "(formerly GenetikaPlus)"

Current AI-Assisted Psychiatric Treatment | NeuroKaire (formerly GenetikaPlus)

↓

Recommended Genetic Testing for Psychiatric Medications | NeuroKaire (56 characters) • "genetic testing for psychiatric medications" = 500/mo, KD 9 • Content Gap: competitors rank 1–7, NeuroKaire absent — easy win

Meta Description (Target: 120–155 chars)

134 chars — in range but could be stronger

Current Discover how AI-assisted psychiatric treatment and precision medicine help clinicians match patients with the right medication faster.

↓

Recommended Support antidepressant prescribing with genetic testing for psychiatric medications. BrightKaire measures neuronal drug response for resistant depression. (154 characters) • "genetic testing for psychiatric medications" = 500/mo, KD 9 • "antidepressant" = 40,500/mo parent • "resistant depression" relates to "treatment resistant depression" = 18,100/mo, Rank #1

H1 Heading (Target: ≤70 chars)

72 chars — over limit Trailing period Product-centric, not clinician-benefit

Current BrightKaire Transforms Brain Health with AI-Assisted Precision Medicine. (72 characters)

↓

Recommended Biological insight to support treatment selection (49 characters — exact language from Update Plan §2.2, Section 7 clinician pathway)

Recommended H2 Structure (sourced from Update Plan §3.1 & §3.2 + existing page)

Guiding prescribers with clinically actionable insights — Existing section (retain)
What happens next Update Plan §3.1 — 4-step clinician process block
Order the test → Patient intake and sample collection → Laboratory analysis → Results available to support care
Clinical studies — Existing section (retain, also cross-linked from /resources per §1.3)
Bring BrightKaire into your practice — Existing onboarding CTA section (retain)
Frequently asked questions Update Plan §3.2
Top 6–8 clinician FAQs in accordion + FAQ schema markup for AEO

5. Evidence / Resources /resources Phase 4

Nav labels: "Evidence" (aggregates proof) and "Resources" both point to /resources per Update Plan §1.1. Phase 4 restructures this page as a credibility hub. The plan contemplates a future dedicated /evidence URL.

depression treatment parent topic · high vol antidepressant research topical cluster depression treatment effectiveness 320/mo · Rank tracked clinical studies + CLIA & CAP

Meta Title (Target: 50–60 chars)

Generic "Resources" — no keywords "(formerly GenetikaPlus)"

Current Resources | NeuroKaire (formerly GenetikaPlus)

↓

Recommended Depression Treatment Research & Evidence | NeuroKaire (53 characters) • "depression treatment" = high-volume parent topic • "depression treatment effectiveness" = 320/mo (tracked) • Establishes topical authority for treatment cluster

Meta Description (Target: 120–155 chars)

141 chars — in range but generic No mention of clinical studies, precision psychiatry, or CLIA

Current Access a wealth of resources from NeuroKaire - articles, case studies, and insights into the latest advancements in psychiatry and neurology.

↓

Recommended Review clinical studies and publications on genetic testing for depression medication. NeuroKaire's CLIA-certified lab delivers peer-reviewed evidence. (151 characters) • "genetic testing" = cluster head • "depression medication" = 49,500/mo parent topic • "clinical studies" + "CLIA" = credibility signals

H1 Heading (Target: ≤70 chars)

Extremely generic — "Resources" (9 chars)

Current Resources (9 characters)

↓

Recommended Evidence and research for depression treatment (46 characters — uses high-volume "depression treatment" parent topic instead of "precision psychiatry" at 30/mo)

Recommended H2 Structure (sourced directly from Update Plan §4.1 Evidence Page Structure)

Clinical validation and laboratory standards Update Plan §4.1
CLIA, CAP, CE Mark credentials
Why evidence matters Update Plan §4.1
STAR*D context, treatment variability, BrightKaire's biological approach
Clinical studies Update Plan §4.1
CMS collection, 4–6 featured items, links to dedicated study pages
Selected scientific publications Update Plan §4.1
Peer-reviewed papers, 4 featured, filtered from Resources CMS
In the press Update Plan §4.1
4–6 media highlights, prioritize funding/regulatory credibility
Leadership perspectives Update Plan §4.1
Podcasts & talks (extensible via CMS)
Our approach to research Update Plan §4.1
HIPAA compliance, de-identified data, ongoing validation

6. About /about-us Phase 5

Nav label is "About" per Update Plan §1.1. Phase 5 rebuilds this page as the narrative home for mission, differentiation, and investor content relocated from Homepage. Careers moves to footer per §5.3.

NeuroKaire 210/mo · branded artificial intelligence mental health 2,900/mo · Rank #1 depression treatment parent topic · high vol antidepressant medication 40,500/mo · Rank #1

Meta Title (Target: 50–60 chars)

"(formerly GenetikaPlus)" Generic "About Us" label

Current About Us | NeuroKaire (formerly GenetikaPlus)

↓

Recommended About NeuroKaire | Depression Treatment Technology (50 characters) • "NeuroKaire" = 210/mo (branded) • "depression treatment" = high-volume parent topic • Replaces "Precision Psychiatry Company" (30/mo for "precision psychiatry")

Meta Description (Target: 120–155 chars)

125 chars — in range but vague No mention of neurons, AI, or depression focus

Current Discover the story behind NeuroKaire - our mission, vision, and dedicated team revolutionizing psychiatry and neurology care.

↓

Recommended NeuroKaire uses patient-derived neurons, genomics, and AI to transform depression treatment. Meet the team behind antidepressant medication testing. (148 characters) • "depression treatment" = parent topic • "antidepressant medication" = 40,500/mo, Rank #1 • "AI" signals "artificial intelligence mental health" = 2,900/mo, Rank #1

H1 Heading (Target: ≤70 chars)

Extremely generic — "About Us" (8 chars)

Current About Us (8 characters)

↓

Recommended Why biology matters in depression care (38 characters — exact hero headline from Update Plan §5.0)

Recommended H2 Structure (sourced directly from Update Plan §5.0 & §5.2)

Our mission Update Plan §5.0
Treatment decisions guided by biology, not guesswork
The big idea Update Plan §5.0
Biology first, reducing uncertainty, designed for real care
How it’s different Update Plan §5.0
Functional neuronal response vs. metabolic genetic tests
How this approach works Update Plan §5.0
4-step process: clinical order → biological sampling → functional analysis → treatment guidance
The vision behind NeuroKaire Update Plan §5.0
Founding motivation + embedded video
Looking ahead Update Plan §5.0
Expansion beyond depression, extensible platform
Origin story Update Plan §5.0
Our team Update Plan §5.0
Leadership, Board, Scientific Advisory profiles
Where we work Update Plan §5.0
Kearny, NJ & Tel Aviv, Israel
Partners and recognition Update Plan §5.0
Logos, awards, credibility visuals (reuse homepage ribbon)

Quick Reference: All Recommended Elements

Meta Titles & H1 Headings

Nav Label	Recommended Meta Title	Chars	Primary Keyword Volume	Recommended H1	Chars
Homepage	Genetic Testing for Depression Medication \| NeuroKaire	54	"genetic testing for medication" 1,500/mo KD 24; "depression medication" 49,500/mo	Move beyond antidepressant trial-and-error	42
How It Works	How Antidepressant Response Testing Works \| NeuroKaire	54	"antidepressant" 40,500/mo Rank #1; differentiates from pharmacogenomics	How BrightKaire antidepressant testing works	44
For Individuals	Genetic Testing for Antidepressants \| NeuroKaire	48	"genetic testing for antidepressants" 1,200/mo KD 6	Understand which antidepressants may work for you	49
For Clinicians	Genetic Testing for Psychiatric Medications \| NeuroKaire	56	"genetic testing for psychiatric medications" 500/mo KD 9	Biological insight to support treatment selection	49
Evidence	Depression Treatment Research & Evidence \| NeuroKaire	53	"depression treatment" high-vol parent topic	Evidence and research for depression treatment	46
About	About NeuroKaire \| Depression Treatment Technology	50	"NeuroKaire" 210/mo branded; "depression treatment" parent topic	Why biology matters in depression care	38

Meta Descriptions

Nav Label	Recommended Meta Description	Chars	Keywords Used (Volume)
Homepage	Move beyond antidepressant trial-and-error. NeuroKaire genetic testing reveals how your neurons respond to depression medication before treatment.	146	"antidepressant" 40,500/mo; "genetic testing" cluster; "depression medication" 49,500/mo
How It Works	See how NeuroKaire measures antidepressant response at the neuronal level using patient-derived neurons, genomics, and AI. CLIA-certified testing.	146	"antidepressant" 40,500/mo Rank #1; "neuronal" differentiator vs. pharmacogenomics
For Individuals	Which antidepressant medication is right for you? BrightKaire genetic testing for antidepressants guides depression treatment before trial-and-error.	149	"antidepressant medication" 40,500/mo Rank #1; "genetic testing for antidepressants" 1,200/mo KD 6
For Clinicians	Support antidepressant prescribing with genetic testing for psychiatric medications. BrightKaire measures neuronal drug response for resistant depression.	154	"genetic testing for psychiatric medications" 500/mo KD 9; "treatment resistant depression" 18,100/mo Rank #1
Evidence	Review clinical studies and publications on genetic testing for depression medication. NeuroKaire's CLIA-certified lab delivers peer-reviewed evidence.	151	"genetic testing" cluster; "depression medication" 49,500/mo parent
About	NeuroKaire uses patient-derived neurons, genomics, and AI to transform depression treatment. Meet the team behind antidepressant medication testing.	148	"depression treatment" parent; "antidepressant medication" 40,500/mo Rank #1; "AI" → 2,900/mo Rank #1

Keyword-to-Page Assignment (Anti-Cannibalization)

Each primary title keyword is assigned to exactly one page to prevent internal competition. Secondary/parent-topic keywords may appear in meta descriptions across pages since descriptions don't carry the same ranking weight as titles.

Primary Title Keyword	Assigned Page	Volume	KD	Source
genetic testing for [depression] medication	Homepage	1,500/mo	24	Content Gap
antidepressant response testing	How It Works	40,500/mo parent	—	Keyword List (Rank #1 for "antidepressant medication")
genetic testing for antidepressants	For Individuals	1,200/mo	6	Content Gap
genetic testing for psychiatric medications	For Clinicians	500/mo	9	Content Gap
depression treatment [research]	Evidence	parent topic	—	Topical authority
NeuroKaire (branded)	About	210/mo	—	Keyword List

Implementation Notes

Title tags and meta descriptions can be updated immediately in Webflow’s Page Settings → SEO Settings for each page, regardless of which content phase is active.
H1 changes require editing page content directly in Webflow. Coordinate H1 updates with the corresponding phase (e.g., don’t change the About H1 to "Why biology matters in depression care" until Phase 5 content is ready).
H2 structures should be implemented alongside their corresponding phase content. The section headings listed above are taken directly from the Update Plan to ensure SEO and content move in lockstep.
FAQ Schema Markup: When adding FAQ accordion sections to /patients and /brightkaire-clinicians (Phase 3, §3.2), implement FAQPage structured data for AEO/featured snippet eligibility.
Verification: After updating, run a fresh Screaming Frog crawl to confirm all changes are live. Monitor Google Search Console for indexing status changes over 2–4 weeks.

Phased Implementation Timing

Element	Can Update Now	Update with Phase	Notes
All meta titles	Yes	—	Independent of content changes
All meta descriptions	Yes	—	Independent of content changes
How It Works H1	Yes	Phase 1	Aligns with nav label change
Homepage H1 + H2s	—	Phase 2	Coordinate with content subtraction
Individuals H1 + H2s	—	Phase 3	Includes "What happens next" + FAQ sections
Clinicians H1 + H2s	—	Phase 3	Includes "What happens next" + FAQ sections
Evidence H1 + H2s	—	Phase 4	Requires full page restructuring
About H1 + H2s	—	Phase 5	Requires relocated homepage content